December 2019—The FDA granted breakthrough therapy designation to Novartis’ capmatinib (INC280) as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer. The designation was granted based on positive primary results from the GEOMETRY mono-1 study.
Novartis, 862-778-2100